An Open-Label, Multicenter Study Evaluating The Safety Of Lasofoxifene In Combination With Abemaciclib For The Treatment Of Pre And Postmenopausal Women With Locally Advanced Or Metastatic Er+/Her2-Breast Cancer And Have An Esr1 Mutation